We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen
receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was …

Summary This Good Practice Paper provides recommendations for the diagnosis and initial
management of transplant‐eligible high‐risk myeloma patients. It describes recent updates …

Simple Summary Patients who are diagnosed with multiple myeloma are given an initial
sequence of treatments that usually, for those who are young and fit enough, includes high …

COI notes: Competing interests: RB reports consulting: BMS, Caribou Biosciences,
Genentech, Janssen, Pfizer, Sanofi, SparkCures; Research: Novartis, Pack Health. CP …

Multiple myeloma is a hematologic malignancy that is typically associated with recurrent
relapses. There are numerous frontline treatment regimens that are highly effective for …

Upfront autologous stem cell transplant (ASCT) is the standard of care for newly diagnosed
multiple myeloma (MM) patients. However, relapse is ubiquitous and therapy-related …

Simple Summary The emergence of new therapeutic agents for multiple myeloma (MM) over
the last 2 decades has resulted in a significant improvement in overall survival (OS) …

The optimal duration of lenalidomide (Len) maintenance for patients with multiple myeloma
(MM) after autologous stem cell transplantation (autoHCT) is unknown. We conducted a …

Identifying patients who may benefit from autologous stem cell transplantation (ASCT) in
newly diagnosed multiple myeloma is crucial, especially in the era of effective induction and …

Patients with multiple myeloma (MM) who undergo high-dose chemotherapy and
autologous hematopoietic cell transplantation (Auto-HCT) have an increased risk of …